Hims & Hers Health, Inc.

HIMS Healthcare Drug Manufacturers Specialty & Generic

Hims & Hers Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 59.0% from fiscal 2024.

Revenue
+38.3%
EPS
−294.7%
Free cash flow
+5.09%
Total debt
+40.8%

Quarter to June 2026, against a year earlier

25.52 1.46 +6.07%
Market cap
$5.6B
P/E
0.0×
Fwd P/E
−49.4×
Dividend yield
—
F-score
4/9
Altman Z
4.10
Beneish M
n/a
Dividend safety
n/a

Hims & Hers Health, Inc. 10-Q filed Aug 10, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 4:17 PM ET · Document on sec.gov · Filing index

What changed

Part II, Item 1A, Risk Factors, against the 10-Q filed May 11, 2026: 32 added · 17 removed · 118 modified; 14 moved without change